In order to detect the hypothesis that prolonged exposure to TMZ improves prognosis in patients with newly diagnosed GBM, a randomized phase III clinical trial was initiated, but it is regrettable that the study did not demonstrate improved efficacy for dose-dense TMZ in newly diagnosed GBM patients, regardless of MGMT methylation status, and there was increased grade ≥ 3 toxicity in dose-dense TMZ group (8). Here, MGMT is linked to glioblastoma.